About Anebulo Pharmaceuticals, Inc.
https://www.anebulo.comAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
CEO
Richard Anthony Cunningham
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
22NW, LP
Shares:15.47M
Value:$17.17M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:3.04M
Value:$3.37M
MANGROVE PARTNERS
Shares:2.53M
Value:$2.8M
Summary
Showing Top 3 of 23
About Anebulo Pharmaceuticals, Inc.
https://www.anebulo.comAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $2.26M ▼ | $-2.16M ▼ | 0% | $-0.05 ▲ | $-2.14M ▼ |
| Q4-2025 | $0 | $2.33M ▲ | $-2.14M ▼ | 0% | $-0.05 ▼ | $-2.13M ▼ |
| Q3-2025 | $0 | $1.89M ▼ | $-1.68M ▲ | 0% | $-0.04 ▲ | $-1.43M ▲ |
| Q2-2025 | $0 | $2.59M ▲ | $-2.46M ▼ | 0% | $-0.09 ▼ | $-2.4M ▼ |
| Q1-2025 | $0 | $2.41M | $-2.2M | 0% | $-0.08 | $-1.87M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $10.35M ▼ | $10.7M ▼ | $963.82K ▲ | $9.74M ▼ |
| Q4-2025 | $11.63M ▼ | $12.15M ▼ | $487.69K ▼ | $11.66M ▼ |
| Q3-2025 | $13.28M ▼ | $14.01M ▼ | $546.03K ▼ | $13.46M ▼ |
| Q2-2025 | $15M ▲ | $15.84M ▲ | $878.8K ▲ | $14.96M ▲ |
| Q1-2025 | $1.4M | $2.47M | $569.23K | $1.9M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.16M ▼ | $-1.27M ▲ | $0 | $0 | $-1.27M ▲ | $-1.27M ▲ |
| Q4-2025 | $-2.14M ▼ | $-1.65M ▼ | $0 | $0 ▲ | $-1.65M ▲ | $-1.65M ▼ |
| Q3-2025 | $-1.68M ▲ | $-1.6M ▼ | $0 | $-116.66K ▼ | $-1.72M ▼ | $-1.6M ▼ |
| Q2-2025 | $-2.46M ▼ | $-1.41M ▲ | $0 | $15M ▲ | $13.59M ▲ | $-1.41M ▲ |
| Q1-2025 | $-2.2M | $-1.69M | $0 | $0 | $-1.69M | $-1.69M |
CEO
Richard Anthony Cunningham
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
22NW, LP
Shares:15.47M
Value:$17.17M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:3.04M
Value:$3.37M
MANGROVE PARTNERS
Shares:2.53M
Value:$2.8M
Summary
Showing Top 3 of 23